NDC-011 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

9,642 results for “NDC-011”

Trials

View all 4705 →

Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy Volunteers

33 participants · First posted Oct 19, 2023

Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)

570 participants · First posted Jul 30, 2024

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

15 participants · First posted Jan 12, 2022

Drugs

View all 3530 →

NDC-002

NDC-1308

NDC-1187

Organizations

View all 34 →

Ndc Inc

United States

Adenovir Pharma AB

Sweden

DUBAI HEALTH AUTHORITY

United Arab Emirates

News

View all 1373 →

DR.NOAH Biotech's AI-Driven ALS Drug, NDC-011, Receives FDA Approval for Phase 1 Trial

Mythic Therapeutics' MYTX-011 Shows Promising Efficacy in Phase 1 Trial for Advanced NSCLC

Alethio Therapeutics Unveils ATX-011, First-in-Class Mutation-Agnostic Antibody for Essential Thrombocythemia Treatment

Page 1 of 965